ImmunOS Therapeutics

1. Executive Summary (Confidence: High)

ImmunOS Therapeutics AG is a high-impact leader in the myeloid checkpoint field, leveraging its unique HLA-based technology to redefine immuno-oncology. The company achieved a major financial milestone in 2023 by closing an oversubscribed $74 million Series B financing round led by premier investors Samsara BioCapital and Lightspeed Venture Partners. ImmunOS has successfully transitioned its lead program, IOS-1002, into Phase 1b clinical trials, reporting significant efficacy results at the ESMO Congress in October 2025. Specifically, IOS-1002 demonstrated a 71% disease control rate in patients with PD-1 resistant cancers when combined with pembrolizumab, signaling a major potential breakthrough for patients with limited therapeutic options. With a strong transatlantic team and a pipeline expanding into inflammatory diseases, ImmunOS is strategically positioned as a frontrunner in the next generation of multifunctional immunotherapies.